XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents (Note 6) $ 2,380.8 $ 2,067.0
Short-term investments (Note 6) 113.1 144.8
Accounts receivable, net of allowances of $13.4 (2023) and $16.0 (2022) 8,167.1 6,896.0
Other receivables 2,196.7 1,662.9
Inventories 4,901.4 4,309.7
Prepaid expenses and other current assets 5,247.9 2,954.1
Total current assets 23,007.0 18,034.5
Investments (Note 6) 2,691.7 2,901.8
Goodwill 4,085.2 4,073.0
Other intangibles, net 6,781.7 7,206.6
Deferred tax assets 4,574.8 2,792.9
Property and equipment, net of accumulated depreciation of $10,767.8 (2023) and $10,233.4 (2022) 11,863.2 10,144.0
Other noncurrent assets 4,911.9 4,337.0
Total assets 57,915.5 49,489.8
Current Liabilities    
Short-term borrowings and current maturities of long-term debt 2,244.7 1,501.1
Accounts payable 2,435.1 1,930.6
Employee compensation 1,233.2 1,059.8
Sales rebates and discounts 11,522.3 8,784.1
Dividends payable 0.0 1,017.2
Income taxes payable 1,977.5 475.1
Other current liabilities 2,585.4 2,370.3
Total current liabilities 21,998.2 17,138.2
Other Liabilities    
Long-term debt 17,923.6 14,737.5
Accrued retirement benefits (Note 8) 1,311.9 1,305.1
Long-term income taxes payable 3,468.3 3,709.6
Other noncurrent liabilities 1,906.1 1,824.0
Total other liabilities 24,609.9 21,576.2
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity    
Common stock 593.6 594.1
Additional paid-in capital 7,160.0 6,921.4
Retained earnings 10,309.9 10,042.6
Employee benefit trust (3,013.2) (3,013.2)
Accumulated other comprehensive loss (Note 10) (3,784.9) (3,844.6)
Cost of common stock in treasury (45.0) (50.5)
Total Eli Lilly and Company shareholders' equity 11,220.4 10,649.8
Noncontrolling interests 87.0 125.6
Total equity 11,307.4 10,775.4
Total liabilities and equity $ 57,915.5 $ 49,489.8